Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Prochlorperazine Maleate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Prochlorperazine maleate inhibits the action of a chemical called dopamine in the brain by blocking D2 dopamine receptors in the brain. It can also block histaminergic, cholinergic, and noradrenergic receptors. It is indicated for the treatment of schizo...
Brand Name : Compazine-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 20, 2023
Lead Product(s) : Prochlorperazine Maleate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Prochlorperazine Maleate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Biophore India Pharmaceuticals Pvt Ltd
Deal Size : Not Applicable
Deal Type : Not Applicable
ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP
Details : The current annual U.S. market for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg is approximately $30.0 million, according to IQVIA/IMS Health, a leading healthcare data and analytics provider.
Brand Name : Prochlorperazine Maleate-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 29, 2022
Lead Product(s) : Prochlorperazine Maleate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Biophore India Pharmaceuticals Pvt Ltd
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?